	Laboratories	PATIENT: Sample Report				TEST REF: TST-XXXXX	
Nordic		TEST NUMBER:	######	COLLECTED:	mm/dd/yyyy	PRACTITIONER: Nordic Laboratori	New distate the sustaining
		PATIENT NUMBER:	######	RECEIVED:	mm/dd/yyyy		Nordic Laboratories
		GENDER:	Male	TESTED:	mm/dd/yyyy	ADDRESS:	XXXXXXXXXXXXX
		AGE	51				
		DATE OF BIRTH:	mm/dd/yyyy				
		AGE DATE OF BIRTH:	51 mm/dd/yyyy	TESTED.	mm/dd/yyyyy	ADDRESS.	^^^^

TEST NAME: Male Hormonal Health

Male Hormonal Health

			Roforonco Bongo
			Reference Range
<30			70-310 mcg/dL
	Gender	Age	Reference Range
	Female	20 to 29 yrs	65-380 mcg/dL
		30 to 39 yrs	45-270 mcg/dL
		40 to 49 yrs	32-240 mcg/dL
		50 to 59 yrs	30-200 mcg/dL
		60 to 69 yrs	30-130 mcg/dL
		Over 69 yrs	30-90 mcg/dL
	Male	20 to 29 yrs	280-640 mcg/dL
		30 to 39 yrs	120-520 mcg/dL
		40 to 49 yrs	95-530 mcg/dL
		50 to 59 yrs	42.290 mcg/dL
		Over 69 yrs	30-175 mcg/dL
	(15)		7 100 pmol//
	15		7-100 hmoi/L
	66		
		Phase	Reference Rang
		Follicular	20-160 pg/mL
		Luteal	27-246 pg/mL
		Menopausal	20-24 pg/mL
		Menopausal + H	RT 20-160 pg/mL
		Male	<= 56 pg/mL
	4.18		
		Phase	Reference Range
		Follicular	0.45-3.17 pg/mL
		Luteal	0.46-2.48 pg/mL
		Menopausal	0.29-1.73 pg/mL
		Menopausal + HF	RT 0.45-3.17 pg/mL
		Male	8.69-54.69 pg/mL
8.3			29.0-90.0 ng/dL
		Gondor	
			Reference Range
		Female	3.0-28.0 ng/dL
		Gender Female Male 15 66 4.18	Gender Age Female 20 to 29 yrs 30 to 39 yrs 40 to 49 yrs 50 to 59 yrs 60 to 69 yrs Over 69 yrs 30 to 39 yrs 40 to 49 yrs 50 to 59 yrs 60 to 69 yrs Male 20 to 29 yrs 30 to 39 yrs 40 to 49 yrs 50 to 59 yrs 60 to 69 yrs 0ver 69 yrs 0ver 69 yrs 66

Nygade 6, 3.sal • 1164 Copenhagen K • Denmark Tel: +45 33 75 10 00 11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK Tel: +44 (0)1580 201 687 www.nordic-labs.com info@nordic-labs.com

© Copyright 2016 Nordic Laboratories. Reproduction may be made for personal use only. Systematic electronic or print reproduction and distribution including duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper are prohibited.

		PATIENT: Sample Report				TEST REF: TST-XXXXX	
Nordic Laboratories		TEST NUMBER:	#######	COLLECTED:	mm/dd/yyyy	PRACTITIONER:	Nordic Laboratories
	GENDER:	Male	TESTED:	mm/dd/yyyy	ADDRESS:	xxxxxxxxxxxx	
	AGE DATE OF BIRTH:	51 mm/dd/yyyy					

TEST NAME: Male Hormonal Health

o Results Continued		
		Reference Range
71		87-215 ng/mL
Г	Age	Reference Range
F	21 to 30 yrs	128-315 ng/mL
	31 to 40 yrs	114-289 ng/mL
	41 to 50 yrs	86-249 ng/mL
	51 to 60 yrs	87-215 ng/mL
	61 to 70 yrs	75-230 ng/mL
	p Results Continued	Age 21 to 30 yrs 31 to 40 yrs 51 to 60 yrs 61 to 70 yrs

Nordic Laboratories Aps

Nygade 6, 3.sal • 1164 Copenhagen K • Denmark Tel: +45 33 75 10 00 11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK Tel: +44 (0)1580 201 687 www.nordic-labs.com info@nordic-labs.com

© Copyright 2016 Nordic Laboratories. Reproduction may be made for personal use only. Systematic electronic or print reproduction and distribution including duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper are prohibited.

UK Office:



PATIENT: Sample Report

TEST NUMBER:	#######
PATIENT NUMBER:	#######
GENDER:	Male
AGE	51
DATE OF BIRTH:	mm/dd/yyyy

COLLECTED:	mm/dd/yyyy
RECEIVED:	mm/dd/yyyy
ESTED:	mm/dd/yyyy

TEST REF: TST-XXXXX

PRACTITIONER: Nordic Laboratories
ADDRESS: XXXXXXXXXXXXX

TEST NAME: Male Hormonal Health

Commentary

Lab Comments

**Requisition/Sample labeling discrepancy noted. Ordering physician has been contacted and authorizes testing to be performed. 02/19/08 SDG

The performance characteristics of all assays have been verified by Genova Diagnostics, Inc. Unless otherwise noted with * as cleared by the U.S. Food and Drug Administration, assays are For Research Use Only.

Commentary is provided to the practitioner for educational purposes, and should not be interpreted as diagnostic or treatment recommendations. Diagnosis and treatment decisions are the responsibility of the practitioner.

Dehydroepiandrosterone-sulfate (DHEA-S) circulates in a higher concentration than any other steroid, is derived from the adrenal gland in response to ACTH, and is the storage form for DHEA. This anabolic hormone serves as a precursor to other androgens such as androstenedione and testosterone, which may, in turn, be enzymatically converted to estrogens in peripheral tissues such as adipose and bone. DHEA-S also plays an important role in thyroid function, immune regulation, maintenance of libido and lean body mass, insulin sensitivity, and balancing the body's stress response. DHEA-S levels peak between the ages of 20 and 30 years, thereafter decreasing markedly, along with downstream androgens and estrogens. Low DHEA-S may be indicative of chronic stress (increased production of cortisol relative to DHEA) or adrenal insufficiency, and has been noted in conditions such as lupus, insulin resistance, osteoporosis, chronic illness, chronic fatigue, depression, neurodegenerative diseases, high-dose glucocorticoid therapy, and breast cancer.

Sex hormone-binding globulin (SHBG) is synthesized primarily in the liver and serves as a protein carrier for Estradiol (E2), testosterone, and dihydrotestosterone (DHT). The biologic effects of these steroid hormones (especially testosterone) are largely determined by the unbound portion. Thus, SHBG exerts a major regulatory effect on bioactivity of these steroids. Since SHBG concentrations determine bioavailability of E2, testosterone, and DHT, normal levels of SHBG are considered protective against conditions associated with excessive androgenic and estrogenic activity such as breast cancer, as well as conditions associated with deficient activity such as osteoporosis. Check individual levels of these hormones for a more thorough evaluation.

Estradiol (E2) is the most potent estrogen. E2 may arise from E1 (reversible reaction) or from testosterone in peripheral tissues such as adipose. Estrogens promote vasodilatation and vascular smooth muscle tone, collagen production, brain activity, and also inhibit bone resorption.

Free testosterone represents the fraction of testosterone that is not bound to sex hormone binding globulin (SHBG), therefore bioavailable. High levels of Free Testosterone are commonly due to supplementation with testosterone, androstenedione, or DHEA, especially in women. A lower concentration of SHBG (such as occurs with hyperinsulinemia or hypothyroidism) will lead to higher levels of Free Testosterone. Other possible causes of elevated Free Testosterone include polycystic ovarian syndrome (PCOS), adrenal tumors, testicular tumors, Cushing's disease and/or congenital adrenal hyperplasia (CAH). Low Free Testosterone is usually due to age-related decline or hypogonadal function. A higher concentration of SHBG (such as occurs with hyperthyroidism or oral estrogen replacement) can also lead to lower levels of Free Testosterone. Men may benefit from testosterone replacement, whereas women may do well with DHEA or androstenedione.

Nordic Laboratories Aps

Nygade 6, 3.sal • 1164 Copenhagen K • Denmark Tel: +45 33 75 10 00 UK Office: 11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK Tel: +44 (0)1580 201 687

www.nordic-labs.com info@nordic-labs.com

© Copyright 2016 Nordic Laboratories. Reproduction may be made for personal use only. Systematic electronic or print reproduction and distribution including duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper are prohibited.



PATIENT: Sample Report

 TEST NUMBER:
 ######

 PATIENT NUMBER:
 ######

 GENDER:
 Male

 AGE
 51

 DATE OF BIRTH:
 mm/dd/yyyy

COLLECTED: mm/dd/yyyy RECEIVED: mm/dd/yyyy TESTED: mm/dd/yyyy

TEST REF: TST-XXXXX

PRACTITIONER: Nordic Laboratories
ADDRESS: XXXXXXXXXXXXX

TEST NAME: Male Hormonal Health

Commentary

Low levels of DHT indicate general androgen deficiency or poor 5-alpha reductase activity. Low levels of testosterone, DHEA and androstenedione can be causative factors of reduced DHT levels. This may result in diminished sex drive and poor muscle tone.

Human growth hormone (hGH) from the pituitary promotes healthy aging via its growth-stimulating and healing effects on a variety of systems, including musculoskeletal, neurological, immune, and endocrine. Because of the pulsatile secretion of hGH, indirect serologic assessment of hGH is best accomplished by measuring insulin like growth factor-1 (IGF-1, or somatomedin C), which is released from the liver and other tissues in response to growth hormone and which mediates many of hGH's actions. Greater than 95% of total IGF-1 is bound to IGF binding proteins that limit its bioavailability. Low levels of IGF-1 suggest insufficient hGH. Low IGF-1 levels have been associated with fatigue, decreased psychological well-being, reduced exercise tolerance, bone density and lean muscle mass, diminished renal function, a tendency toward low blood sugar, and an overall diminished ability for growth and repair. Levels of growth (and IGF-1) tend to increase with measures such as exercise (especially anaerobic), sleep, reduced-carbohydrate diets, 'secretagogues' (e.g., L-arginine), and/or recombinant hGH administration.

Nordic Laboratories Aps

Nygade 6, 3.sal • 1164 Copenhagen K • Denmark Tel: +45 33 75 10 00 11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK Tel: +44 (0)1580 201 687

www.nordic-labs.com info@nordic-labs.com

© Copyright 2016 Nordic Laboratories. Reproduction may be made for personal use only. Systematic electronic or print reproduction and distribution including duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper are prohibited.

UK Office: